{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-006906","form_type":"8-K","ticker":"SRRK","cik":"0001727196","company_name":"Scholar Rock Holding Corp","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.766073+00:00","generated_at":"2026-06-02T19:16:37.213903+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Scholar Rock Q1 net loss $56.9M ($0.59/shr); Phase 3 SMA data on track for Q4 2024","bullets":["Net loss $56.9M ($0.59/shr) vs $39.4M ($0.49) Q1 2023; no revenue; R&D up 45% to $43.1M.","Cash $238M as of March 31, 2024; expected to fund operations into 2H 2025.","Phase 3 SAPPHIRE top-line data for apitegromab in SMA on track for Q4 2024; potential commercial launch in 2025 if successful.","Initiating Phase 2 proof-of-concept trial of apitegromab + GLP-1 RA in obesity in June 2024; data expected mid-2025.","SRK-181 data selected for oral presentation at ASCO 2024; SRK-439 preclinical data at ADA 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-006906","json":"https://secwatch.observer/filing/0001558370-24-006906.json","markdown":"https://secwatch.observer/filing/0001558370-24-006906.md","text":"https://secwatch.observer/filing/0001558370-24-006906.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024006906/0001558370-24-006906-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024006906/srrk-20240507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:16:37.213903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68256d92ddeb55cea3dcd8c970bb658e78962b61","claim":"Scholar Rock Holding Corp reported the quarter ended March 31, 2024 results: revenue no revenue, net income net loss was $56.9 million or $0.59 per share, EPS $0.59 per share.","evidence_excerpt":"For the quarter ended March 31, 2024, net loss was $56.9 million or $0.59 per share compared to a net loss of $39.4 million or $0.49 per share for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1727196/000155837024006906/0001558370-24-006906-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"no revenue"},{"label":"Net income","value":"net loss was $56.9 million or $0.59 per share"},{"label":"EPS","value":"$0.59 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}